Monday June 1, 2026
A holiday-shortened week — the NYSE was closed Memorial Day Monday — but four trading days still delivered a heavy run of deals, recalls, and a regulatory shift reshaping the wearables market.
The week’s signal was risk and capital moving at once. Quality problems surfaced inside two of the industry’s biggest franchises while the consolidation engine kept running — Olympus, Boston Scientific, and DePuy Synthes all put money to work — and the FDA’s looser posture on wellness claims opened the floodgates on consumer blood-pressure features. All eyes now turn to Wednesday, when Medtronic closes out the sector’s earnings season..
8 things to watch this week:
1. 📊 Medtronic shares slide into Wednesday’s fiscal Q4 report
Medtronic fell roughly 6% in the holiday-shortened week, closing at $73.81 after four straight down sessions, ahead of fiscal Q4 and full-year results due before the open on June 3. The print caps the sector’s earnings season and follows the company’s $650M deal for SPR Therapeutics — a read on whether its growth-by-acquisition strategy is convincing investors.
TS2
2. 🫀 Boston Scientific funnels $1.5B into MiRus with an option to buy its TAVR system
Boston Scientific took a 34% stake in MiRus and secured an exclusive option to acquire its Siegel balloon-expandable TAVR platform for an additional $3 billion. The structured, optioned deal is a notable template — a route back into structural heart after exiting Acurate, without taking on full development risk up front.
Fierce Biotech
3. 🧭 Most medical device companies don’t fail on technology. They fail on sequencing.
The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.
The CLIF Analysis from RŌG Health is a quick, structured external diagnostic that helps you identify gaps before they become costly. One week. Built for medical device and medtech teams.
Sponsored by RŌG Health
4. 💍 Blood-pressure wearables flood the market after the FDA relaxes oversight
After January guidance let companies ship sensors that “estimate, infer, or output” blood pressure for wellness purposes without authorization, Ōura debuted its Ring 5 with blood-pressure signals — and it’s far from alone. The episode marks a real line companies now have to draw between an unregulated wellness claim and a regulated medical one, and some experts are uneasy about it.
The Boston Globe / STAT
5. 🤖 Cornerstone Robotics wins CE mark for its Sentire surgical robot
The Hong Kong-based company secured EU approval for its AI-powered Sentire endoscopic platform across general surgery, gynecology, thoracic, and urology — its formal entry into Europe, following a $200M raise and early UK clinical work with Portsmouth Hospitals. Early users have noted similarities to Intuitive’s da Vinci, a sign the field’s challengers are converging on a familiar interface to ease adoption.
MassDevice
6. ⚠️ J&J’s Abiomed recalls Impella heart pumps after a patient death
J&J initiated a voluntary recall of seven Impella CP sets that don’t meet design specifications, an issue linked to one death and flagged through the company’s retrospective quality audits. It’s the latest in a long string of Impella actions, and J&J was careful to note the issue appeared in 0.01% of global cases — but the cadence keeps post-Abiomed integration risk in the spotlight.
Cardiovascular Business
7. 💉 Beta Bionics earmarks Q2 2027 for its Mint patch pump launch
Beta Bionics set a Q2 2027 commercialization target for Mint, a patch pump pairing its adaptive dosing algorithm with a 200-unit reservoir, three-day wear, and a two-piece reusable/disposable design — pending FDA clearance as an ACE pump. The tubeless category is getting more crowded just as incumbent Insulet manages quality scrutiny of its own.
Drug Delivery Business News
8. 🔓 Dexcom warns of stolen G7 sensors being resold to the public
Dexcom identified two lots of G7 sensors that were marked as scrap, sent for destruction, then stolen and sold to consumers through an unauthorized distributor. One lot carries a sterilization-related infection risk and the other an elevated failure rate — a supply-chain integrity problem that puts a spotlight on vendors’ end-of-life destruction protocols.
MobiHealthNews
🔎 Bonus: worth a read
Founders face pressure from all sides as biotech crawls toward recovery
A dispatch from Salt Lake City’s Altitude Lab, where biotech founders — first-timers and 20-year veterans alike — talk candidly about raising capital in a risk-averse market that’s chasing AI hype over slow-moving science. A grounded look at the sequencing and storytelling challenges early-stage life science leaders are navigating right now.
BioSpace
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.